Gold soars to record high over $3,900/oz amid yen slump, US rate cut bets
Director Robert W. Duggan of Pulse Biosciences, Inc. (NASDAQ:PLSE), a $976 million market cap company, has recently purchased shares of the company’s common stock, according to a Form 4 filing with the Securities and Exchange Commission. According to InvestingPro data, the stock is currently trading near its 52-week low of $13.77, with analysts setting a $22 price target.
The reported transactions, all purchases, took place between September 11, 2024, and September 10, 2025. Duggan acquired a total of 175,499 shares for approximately $2.79 million.
Specifically, on September 10, 2025, Duggan bought 34,659 shares. The price per share for this transaction ranged from $14.51 to $14.81. On September 11, 2024, Duggan purchased 12,800 shares, with prices ranging from $14.57 to $14.79 per share. The final transaction occurred on September 12, 2024, with Duggan buying 145,140 shares; the price per share for this transaction ranged from $13.90 to $14.75.
Following these transactions, Duggan directly owns 47,709,140 shares of Pulse Biosciences. He also indirectly owns 630,109 shares through Genius 24C Inc., where he is the sole shareholder, and 450,189 shares through Blazon Corporation, where he is also the sole shareholder. Get deeper insights into insider trading patterns and 8 additional key metrics with a comprehensive InvestingPro subscription.
In other recent news, Pulse Biosciences reported its Q2 2025 earnings, highlighting a significant increase in costs and expenses. The company’s net loss widened compared to the previous year, although it maintained strong cash reserves. Additionally, Pulse Biosciences announced that the U.S. Food and Drug Administration approved its Investigational Device Exemption application for the NANOCLAMP AF study. This study will assess the company’s nanosecond Pulsed Field Ablation Cardiac Surgery System for treating atrial fibrillation. In another development, a clinical feasibility study demonstrated the effectiveness of Pulse Biosciences’ nsPFA technology in treating benign thyroid nodules. Conducted in Naples, Italy, the study showed a reduction in nodule size by up to 93% at one year. Patients also reported significant symptom relief shortly after treatment. These recent developments mark important advancements for Pulse Biosciences.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.